ScPharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- ScPharmaceuticals's estimated annual revenue is currently $7.5M per year.
- ScPharmaceuticals's estimated revenue per employee is $48,077
- ScPharmaceuticals's current valuation is $111.9M. (January 2022)
Employee Data
- ScPharmaceuticals has 156 Employees.
- ScPharmaceuticals grew their employee count by 21% last year.
ScPharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO & President | Reveal Email/Phone |
3 | VP Medical Affairs | Reveal Email/Phone |
4 | SVP, Clinical Development and Medical Affairs | Reveal Email/Phone |
5 | Head Quality Assurance | Reveal Email/Phone |
6 | VP, Legal Affairs & Compliance | Reveal Email/Phone |
7 | VP, Head Regulatory Affairs | Reveal Email/Phone |
8 | VP Program Management and Regulatory Affairs | Reveal Email/Phone |
9 | Controller | Reveal Email/Phone |
10 | VP, Head Commercial: Marketing, Market Access, Sales & Operations | Reveal Email/Phone |
What Is ScPharmaceuticals?
N/A
Total Funding
156
Number of Employees
$7.5M
Revenue (est)
21%
Employee Growth %
$111.9M
Valuation
N/A
Accelerator
ScPharmaceuticals News
2022-04-06 - Scpharmaceuticals Inc (SCPH) Stock Loses -13.69% This Week; Should You Buy?
Scpharmaceuticals Inc (SCPH) stock is down -13.28% over the last 12 months, and the average rating from Wall Street analysts is a Buy.
2022-04-06 - scPharmaceuticals Inc. Announces Resubmission of ...
scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application. Anticipates Q4 2022 commercial launch, if approved. April 11,...
2022-04-06 - 5Am Partners Iv, Llc Sells 270000 Shares of ...
scPharmaceuticals Inc. (NASDAQ:SCPH Get Rating) major shareholder 5Am Partners Iv, Llc sold 270,000 shares of the business's stock in a...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 156 | 6% | N/A |
#2 | $42.9M | 156 | 7% | N/A |
#3 | $56.6M | 156 | 10% | N/A |
#4 | $3.5M | 156 | 10% | N/A |
#5 | $28.9M | 156 | -10% | N/A |